Quick Answer
Cullinan Therapeutics, Inc. reported Stockholders Equity of $408.73 million for fiscal year 2025.
Cullinan Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $408.73M | -30.8% |
| 2024 | $590.33M | +30.1% |
| 2023 | $453.70M | -15.2% |
| 2022 | $535.03M | +25.9% |
| 2021 | $424.97M | +113.5% |
| 2020 | $199.01M | +105.2% |
| 2019 | $97.00M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $451.37M | -28.1% | -8.3% |
| June 30, 2025 | $492.15M | -25.0% | -10.8% |
| March 31, 2025 | $551.84M | +29.6% | -6.5% |
| December 31, 2024 | $590.33M | +30.1% | -6.0% |
| September 30, 2024 | $627.86M | +33.9% | -4.3% |
| June 30, 2024 | $656.22M | +31.4% | +54.2% |
| March 31, 2024 | $425.67M | -12.4% | -6.2% |
| December 31, 2023 | $453.70M | -15.2% | -3.2% |
- Cullinan Therapeutics, Inc. showed a decrease of -30.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Cullinan Therapeutics, Inc.’s stockholders equity has grown by 321.4% (from $97.00 million to $408.73 million).
- The most recent figure is from Cullinan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: